N-Acetyl-Ser-Asp-Lys-Pro (TFA)
CAT:
804-HY-P0266A-04
Size:
25 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

N-Acetyl-Ser-Asp-Lys-Pro (TFA)
- UNSPSC Description: N-Acetyl-Ser-Asp-Lys-Pro (TFA), an endogenous tetrapeptide secreted by bone marrow, is a specific substrate for the N-terminal site of ACE.
- Target Antigen: Angiotensin-converting Enzyme (ACE)
- Type: Peptides
- Related Pathways: Metabolic Enzyme/Protease
- Applications: COVID-19-anti-virus
- Field of Research: Inflammation/Immunology; Cardiovascular Disease
- Assay Protocol: https://www.medchemexpress.com/n-acetyl-ser-asp-lys-pro-tfa.html
- Solubility: H2O
- Smiles: O=C([C@@H](CC(O)=O)NC([C@H](CO)NC(C)=O)=O)N[C@@H](CCCCN)C(N1[C@@H](CCC1)C(O)=O)=O.O=C(O)C(F)(F)F
- Molecular Weight: 601.53
- References & Citations: [1]Rousseau A, et al. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specificsubstrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem. 1995 Feb 24;270(8):3656-61.|[2]Pokharel S, et al. N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension. 2002 Aug;40(2):155-61.|[3]Rhaleb NE, et al. N-acetyl-Ser-Asp-Lys-Pro inhibits interleukin-1β-mediated matrix metalloproteinase activation in cardiac fibroblasts. Pflugers Arch. 2013 Oct;465(10):1487-95.|[4]Rhaleb NE, et al. Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice. J Hypertens. 2011 Feb;29(2):330-8.
- Shipping Conditions: Blue Ice
- Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
- Clinical Information: No Development Reported